uniQure (NASDAQ:QURE) Sees Strong Trading Volume

uniQure (NASDAQ:QURE) saw an uptick in trading volume on Wednesday . 54,340,355 shares changed hands during mid-day trading, an increase of 3,277% from the previous session’s volume of 1,609,147 shares.The stock last traded at $10.79 and had previously closed at $6.67.

Analysts Set New Price Targets

A number of research firms have issued reports on QURE. Mizuho decreased their price objective on shares of uniQure from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 8th. HC Wainwright restated a “buy” rating and issued a $25.00 price objective on shares of uniQure in a research report on Tuesday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, uniQure presently has an average rating of “Moderate Buy” and a consensus target price of $23.00.

uniQure Price Performance

The company has a quick ratio of 9.27, a current ratio of 9.39 and a debt-to-equity ratio of 0.70. The firm’s 50-day moving average is $5.08 and its 200-day moving average is $5.39. The company has a market cap of $423.36 million, a PE ratio of -1.40 and a beta of 0.97.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.31) by ($0.05). uniQure had a negative net margin of 1,562.22% and a negative return on equity of 121.60%. The company had revenue of $8.49 million for the quarter, compared to analysts’ expectations of $2.58 million. On average, equities analysts anticipate that uniQure will post -4.45 EPS for the current year.

Institutional Investors Weigh In On uniQure

Several hedge funds have recently bought and sold shares of the business. Vestal Point Capital LP bought a new stake in uniQure during the fourth quarter worth about $26,572,000. Vanguard Group Inc. boosted its stake in uniQure by 11.4% during the first quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock worth $5,577,000 after acquiring an additional 109,740 shares in the last quarter. Citigroup Inc. boosted its stake in uniQure by 667.9% during the third quarter. Citigroup Inc. now owns 766,521 shares of the biotechnology company’s stock worth $5,143,000 after acquiring an additional 666,696 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in uniQure by 4.3% during the first quarter. BNP Paribas Financial Markets now owns 736,724 shares of the biotechnology company’s stock worth $3,831,000 after acquiring an additional 30,054 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its stake in uniQure by 133.1% during the first quarter. Acadian Asset Management LLC now owns 613,490 shares of the biotechnology company’s stock worth $3,189,000 after acquiring an additional 350,291 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.